{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"9.2","value":"7.8"},{"groupId":"OG001","lowerLimit":"6.5","upperLimit":"9.7","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles. For subjects with ORR.","id":"OG000","title":"Carfilzomib (A1) for (ORR)"},{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles. For subjects with CBR.","id":"OG001","title":"Carfilzomib (A1) for (CBR)"}],"paramType":"MEDIAN","populationDescription":"Subjects with overall response within the response-evaluable population were included in the analysis of DOR. See overall analysis population description of response-evaluable population above.","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Duration of Response (A1 Only)","type":"SECONDARY","unitOfMeasure":"months"}